GLP-1 RA for Stage 1 Type 1 Diabetes

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
Children's Hospital Medical Center, Cincinnati
Study ID
NCT07430332
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Stage 1 Diabetes Mellitus, Type 1

Eligibility Criteria

Sex
ALL
Age
12 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Semaglutide — DRUG
    Study participants will be randomized to either placebo or semaglutide treatment for 12 months
  • Placebo — DRUG
    Randomized to either placebo or semaglutide.

Study Details

This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.

Key Dates

Start date
Sep 1, 2027
Status verified
Feb 2026
Primary completion
Jun 1, 2029
Completion
Jan 1, 2030

Study Design

Enrollment
15 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Semaglutide or Placebo Treatment
  • Placebo Comparator: Placebo
    Randomized to placebo or semaglutide

Primary Outcome Measure

C-peptide area under the curve [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cincinnati Children's Hospital Medical CenterCincinnatiOhio45229
Lily Deng, MD
[email protected]
513-636-0002

Find similar trials in Cincinnati, OH

By research site
Cincinnati Children's Hospital Medical Center· Cincinnati, OH